Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Pharma & Biotech

Avacta (AIM: AVCT) FAP-Exd data challenges Enhertu on tumor selectivity ahead of Phase 1 start

Avacta Therapeutics (AIM: AVCT) has published preclinical data showing that its FAP-targeted payload delivery platform, FAP-Exd (AVA6103), outperforms the marketed antibody drug conjugate trastuzumab deruxtecan across three pharmacokinetic measures, with a Phase 1 clinical trial expected to begin in the first quarter of 2026. What the AI-generated comparator actually enables The methodological choice here deserves

Read More
Pharma & Biotech

Scynexis expands SCY-247 program with IV SAD and MAD trial launch

SCYNEXIS advances IV SCY-247 into Phase 1 for invasive candidiasis. Explore what this means for resistance and regulation.

Read More
Pharma & Biotech

Gossamer Bio Phase 3 PROSERA results: what seralutinib’s near miss means for pulmonary arterial hypertension

Gossamer Bio’s Phase 3 PROSERA data for seralutinib in PAH missed its primary endpoint. Read what this means for regulators and clinicians.

Read More
Pharma & Biotech

Quiver Bioscience deal shows how Angelini Pharma is rethinking genetic epilepsy innovation

Angelini Pharma partners with Quiver Bioscience to discover new genetic epilepsy targets. Find out what this changes for drug discovery and patients.

Read More
Pharma & Biotech

Why Beren Therapeutics’ adrabetadex NDA could redefine approval standards in ultra-rare pediatric disease

FDA acceptance of adrabetadex puts disease modification for infantile-onset NPC under review. See what this decision could change for rare disease approvals.

Read More
Pharma & Biotech

GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy

GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.

Read More
Pharma & Biotech

AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV

AiCuris pritelivir shows superior lesion healing in HIV-associated refractory HSV. Explore what the Phase 3 data mean for regulation and practice.

Read More
Pharma & Biotech

Eton Pharmaceuticals expands rare endocrine portfolio with FDA-backed liquid desmopressin

FDA approves DESMODA oral solution for central diabetes insipidus. Explore what this means for dosing precision and rare endocrine care.

Read More
Pharma & Biotech

What Longeveron Inc.’s Phase 2b results mean for regenerative medicine in aging populations

Longeveron Inc. publishes Phase 2b laromestrocel data in frailty. Explore what it means for stem cell therapy and regulatory next steps.

Read More
Pharma & Biotech

Vir Biotechnology’s VIR-5500 tests whether dual-masked T-cell engagers can finally work in metastatic prostate cancer

Vir Biotechnology’s VIR-5500 shows early promise in metastatic prostate cancer. Find out what changes, what remains uncertain, and what comes next.

Read More